Last reviewed · How we verify
Shigella flexneri 2a InvaplexAR
At a glance
| Generic name | Shigella flexneri 2a InvaplexAR |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia (PHASE1)
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: